Ïã¸ÛÁùºÏ²Ê

XClose

Early Phase Cancer Trials Programme at Ïã¸ÛÁùºÏ²Ê and Ïã¸ÛÁùºÏ²ÊH

Home
Menu

Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals

To find more information on Ïã¸ÛÁùºÏ²ÊH Early Phase Cancer Clinical Trials, including eligibility criteria, click theÌýhyperlinkedÌýLocal Project Reference (LRP)ÌýID, which will take you to the Ïã¸ÛÁùºÏ²ÊH Find a Study database.

Additional early phase clinical trials recruiting UrologyÌýcohorts may be found in theÌýAdvanced Solid Tumour Trials Portfolio page.

Ìý

Ìý

DURANCE

DURANCE: ÌýA phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr

Local Project Reference:
Principal Investigator:Dr. Mark Linch
Drug Class/ Treatment:Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody)Ìý+ÌýS-488210/S-488211 (Peptide Vaccine)
Patient Population:Non-Muscle Invasive Bladder Cancer
Trial Hosted By - Ïã¸ÛÁùºÏ²ÊH Cancer Clinical Trials Unit (CCTU)

ABACUS-2

ABACUS-2: ÌýPhase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer

Local Project Reference:
Principal Investigator:Dr. Mark Linch
Drug Class/ Treatment:AtezolizumabÌý(IgG1 Isotype Monoclonal Antibody against PD-L1)
Patient Population:

Patient requiring surgery with:

  • Cohort 1: T1 high grade - T4a of the bladder with mixed (dominant) or rare histological subtype
  • Cohort 2: Upper urinary tract (high grade or high risk)
Trial Hosted By - Ïã¸ÛÁùºÏ²ÊH Cancer Clinical Trials Unit (CCTU)

Ìý

Ìý

Ìý

Ìý

Ìý